Q-omics provides the consensus-scored MIR8089 profile across patient tissues and cancer cell-line models. MIR8089 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MIR8089 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, MIR8089 RNA expression shows 15,456 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight UCS, KIRC, and COAD as cancer lineages where MIR8089 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR8089 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR8089 survival associations across molecular data types. MIR8089 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR8089 RNA expression–survival associations across cancer types. High MIR8089 expression shows unfavorable associations in UCS, BRCA, DLBC and KICH, but favorable associations in KIRC and OV. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify UCS as the clearest survival context for MIR8089 RNA expression.
This table summarizes MIR8089 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR8089. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR8089 shows lower tumor expression in BRCA, LUSC, LUAD and THCA and higher tumor expression in KIRC. The KIRC box plot shows higher MIR8089 RNA expression in tumor versus normal tissue (log2 FC = +0.231, t-test p < 0.001).
This table shows molecular features associated with MIR8089 in patient tissues and cancer cell lines. In patient samples, MIR8089 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
